Subscribe
  
IPQ Inside the global regulatory dialogue

Biosimilar Developer May Gain Edge Over Originator on Structure/Function and Process/Product Knowledge, Sandoz Maintains

Aug 9th, 2012

Please Log in to print the full article

Sandoz has been making the case in recent public presentations, publications and regulatory guidance comments that companies developing biosimilars may end up knowing more about structure/function and product/process relationships than the companies originating the products they are targeting.

The presumption of a knowledge gap between originators and biosimilar developers about these relationships is reflected in the need being voiced for clinical studies on biosimilars to support the analytical comparability work and for additional requirements for interchangeability.

Sandoz is stepping up to the plate to take issue with this presumption – at least for firms like itself with a wealth of knowledge and experience to draw on in both the innovator and biosimilar arenas.

Commenting on the time- and resource-intensive nature of the biosimilar development process at the PDA annual meeting in Phoenix in April, Sandoz Global Head of Pharmaceutical Development Mark McCamish maintained that “as a biosimilar manufacturer, we often know more about the structure/function relationships than the originator.”

[The story continues for subscribers beginning on page 2.  Nonsubscribers can purchase the story for $195 by contacting Wayne Rhodes ([email protected]).  For subscription/license information, click here.]

See related stories:

Regulatory Pathways Are Opening Up Globally for Biosimilars

MedImmune’s Agreement to Produce Merck’s Biosimilars Exemplifies Shifting Biotech Manufacturing Sands

Safety Assurance in Focus at FDA Hearing on Biosimilar Guidance and Policy Refinement

Raft of Comments on FDA Biosimilar Draft Guidances Draw Attention to Protein Definition, Interchangeability and Naming

EMA’s Biosimilar Quality Guideline Redraft Sharpens Focus on Target Profiles and Lifecycle Changes of Reference Product

EMA’s Biotech CMC Focal Points Include Biosimilar Guideline Revisions and Joint Reviews with FDA

FDA’s Proposed Biosimilar User Fee Structure Explained to Congress by CDER’s Woodcock

FDA Release of Biosimilar Guidance Documents Opens Up New Chapter in Dialogue with Industry

FDA Releases Biosimilar Authorization Performance Goals for Comment as Efforts to Implement the New Act Continue

Make Interchangeability Decision After Biosimilar Approval, Amgen Urges FDA

Pages: 1 2

    ©2021 IPQ Publications